Delivery Order SPE2DR25D7064-SPE2DR26F2MQL
- Not listed
- The Defense Logistics Agency awarded a $3,638.66 delivery order to AmerisourceBergen Drug Corp for Cipro 5% suspension (100mL) on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,414.24 to AmerisourceBergen Drug Corp for the supply of Ciprofloxacin HCL 500 mg tablets (20-count packages). This competitive award, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contractor will perform fulfillment from its corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Cipro (ciprofloxacin) 250 mg tablets in quantities of 100 units, with a contract ceiling value of $1,564.92. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a pediatric or smaller-quantity pharmaceutical procurement utilizing AmerisourceBergen's existing contract vehicle. The award was not designated as a set-aside and...
- The Defense Logistics Agency awarded a $2,967.88 delivery order to AmerisourceBergen Drug Corp for 100ml of Cipro 5% Suspension on September 5, 2025, with an ultimate completion date of September 8, 2025. This firm fixed price contract represents a non-set-aside award issued under competitive procurement procedures. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Ciprofloxacin HCL 500 mg tablets (100-count units) with a ceiling value of $2,502.88. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by July 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ciprofloxacin HCL 500 mg tablets (100 count) with a contract value of $3,574.21. This competitively awarded, non-set-aside delivery order was issued on September 30, 2025, with an ultimate completion date of October 1, 2025, and reflects a firm fixed-price arrangement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $7,906.61 to AmerisourceBergen Drug Corp for the supply of Ciprofloxacin HCL 500 mg tablets (100-count units) on July 10, 2025, with an ultimate completion date of July 11, 2025. The contract employs firm fixed pricing under a non-competitive, non-set-aside delivery order structure. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate...
- The Defense Logistics Agency awarded a $1,089.72 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Cipro 5% Suspension in 100ml quantities. This firm fixed-price contract, with an ultimate completion date of September 2, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procedures with no set-aside designation, and the product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Ciprofloxacin HCL 500 mg tablets in quantities of 100 units per package. This competitive delivery order, valued at $3,519.85 with firm fixed pricing, is scheduled for completion by October 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,258.12 for Ciprofloxacin 7.5ML on August 26, 2024, with a completion date of August 29, 2024. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor will perform the delivery...
- SPE2DR25D7064Indefinite Delivery Contract
- SPE2DR25D7064-SPE2DR26F2MQLDelivery Order
The Defense Logistics Agency awarded a $2,410.72 delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Ciprofloxacin 400 mg/200 ml in 5% Dextrose solution. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 11, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and represents a child order under a larger contract vehicle. This delivery order falls under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. As a leading pharmaceutical distributor, AmerisourceBergen Drug Corp supplies a comprehensive range of medical products to support military healthcare systems and federal medical procurement needs. The ciprofloxacin supply supports critical antibiotic availability for Defense Health Agency and related federal healthcare operations, consistent with the company's role as a primary source for pharmaceutical commodities across multiple therapeutic domains within the DLA medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 12/9/25 |